A study on mice showed that combining vaccines for breast and colorectal cancer with entinostat, an HDAC inhibitor, resulted in reduced tumor growth, a more pro-inflammatory microenvironment, and increased type 1 effector immune cells [410]. Here, HDAC9 is linked to colorectal cancer.